Global Trends Overview: The Rapid Evolution of the Genomic Cancer Panel and Profiling Market

Understanding the Future Outlook of the Genomic Cancer Panel and Profiling Market
The genomic cancer panel and profiling market is on track for significant expansion over the coming years. By 2030, the market size is projected to reach $15.45 billion, growing at a compound annual growth rate (CAGR) of 8.4%. This uptrend is driven by various factors including the expanding use of companion diagnostics, rising adoption of liquid biopsies, the integration of artificial intelligence in genomic analyses, enhanced oncology screening programs, and the development of more affordable sequencing technologies. Key trends shaping this market include wider acceptance of multi-gene cancer panels, increased use of next-generation sequencing (NGS), growth in liquid biopsy testing, a stronger focus on personalized oncology, and the incorporation of genomic data into clinical decision-making processes.

Leading Players Driving the Genomic Cancer Panel and Profiling Market
Several prominent companies dominate the genomic cancer panel and profiling landscape. These include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Hologic Inc., Illumina Inc., Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, ARUP Laboratories, Tempus Labs, Genscript Biotech Corporation, NeoGenomics Inc., Foundation Medicine, Invitae Corporation, Guardant Health Inc., Caris Life Sciences, Fulgent Genetics, NanoString Technologies Inc., Genecast Biotechnology Co. Ltd, Burning Rock DX, HTG Molecular Diagnostics Inc., and Predictive Oncology Inc. A notable industry development occurred in June 2023 when Quest Diagnostics, a US clinical laboratory firm, acquired Haystack Oncology. This move strengthened Quest Diagnostics' liquid biopsy and cancer detection capabilities by adding Haystack Oncology's innovative liquid biopsy technology portfolio, aimed at early cancer detection and monitoring.

Download a free sample of the genomic cancer panel and profiling market report:
https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Technological Innovations Shaping the Genomic Cancer Panel and Profiling Market
Technology advancements are at the forefront of growth in the genomic cancer panel and profiling sector. Leading companies are focusing on next-generation sequencing (NGS) platforms to enhance diagnostic accuracy, speed, and depth, enabling highly personalized cancer treatment decisions. Next-generation sequencers allow for rapid, high-throughput genetic analyses that identify mutations and other genomic characteristics. For example, in April 2025, Netherlands-based QIAGEN N.V. introduced QIAseq panels tailored for NGS, capable of profiling over 700 genes. These panels are designed for both clinical and research settings to improve cancer diagnosis and treatment planning.

Market Segmentation of the Genomic Cancer Panel and Profiling Industry
The genomic cancer panel and profiling market is segmented based on various criteria to capture its diverse applications:
1) Tissue Testing includes Solid Tissue Testing and Liquid Tissue Testing.
2) Technology types consist of Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), and other technologies.
3) Cancer Panel Type is divided into Single-Gene Panels and Multi-Gene Panels.
4) Application segments cover Clinical and Research uses.
5) End User categories include Hospitals, Research and Academic Institutes, Clinical and Diagnostic Laboratories, and others.

View the full genomic cancer panel and profiling market report:
https://www.thebusinessresearchcompany.com/report/genomic-cancer-panel-and-profiling-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Further breakdown includes:
- Solid Tissue Testing subcategories such as biopsy samples, surgical resection samples, formalin-fixed paraffin-embedded (FFPE) tissues, and fresh frozen tissues.
- Liquid Tissue Testing subsegments include blood, urine, saliva, cerebrospinal fluid (CSF), and other bodily fluids.

This detailed segmentation provides a comprehensive framework to understand the genomic cancer panel and profiling market's structure and target areas.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.